WU CART 007 / Wugen - LARVOL DELTA

Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies. (PubMed, Blood) - P1/2 | "WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356."

Journal • P1/2 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Washington University School of Medicine | Recruiting ➔ Active, not recruiting | N=54 ➔ 6

Enrollment change • Enrollment closed • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Leukemia • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD7

WU-CART-007 Showed Antileukemic Activity, Acceptable Safety in Relapsed/Refractory T-ALL/LBL (Oncology Nurse Advisor) - P1/2 | N=29 | NCT04984356 | Sponsor: Wugen, Inc. | "In patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), treatment with WU-CART-007 was associated with antileukemic activity and an acceptable safety profile in a recent phase 2 study....Among 11 evaluable patients, the objective response rate (ORR) was 91%, with a composite complete remission (CRc) rate of 73%, including 6 complete remissions (CRs) and 2 CRs with incomplete recovery (CRi). Among 6 patients with CRc and available minimal residual disease (MRD) data, the rate of MRD negativity was 83%. Five participants proceeded to allo-HSCT. The median duration of response was not reached (95% CI, 0.5-not estimable; range, 0.5-9.1 months) at the time of reporting, with a follow-up of up to 9.9 months."

P1/2 data • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

WUC007-03: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=125 | Active, not recruiting | Sponsor: Wugen, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 (GlobeNewswire) - "Wugen, Inc...today announced the dosing of the first patients in its pivotal Phase 2 study evaluating WU-CART-007, a potential first-in-class, investigational, anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL)."

Trial status • T Lymphoblastic Lymphoma • T-cell Acute Lymphoblastic Lymphoma

WU-CART-007, an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results (TCT-ASTCT-CIBMTR 2025) - P1/2, P2 | "Patients in phase 2 received a single infusion of 900 million WU-CART-007 cells on Day 1 following lymphodepleting chemotherapy (fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...Cytokine Release Syndrome (CRS) was observed in 100% (13/13), mostly Grade ≤ 2 (69%); four (31%) had ≥ Grade 3, managed with steroids (75%), tocilizumab (100%), anakinra (25%)...WU-CART-007 demonstrated anti-leukemic activity with an acceptable safety profile in heavily pre-treated R/R T-ALL/LBL pts. A follow-up study (NCT06514794) including patients > 1 year old and an exploratory MRDpos cohort will begin enrolling in late 2024."

CAR T-Cell Therapy • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Oncology • Septic Shock • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

WUC007-03: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=125 | Recruiting | Sponsor: Wugen, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

WU-CART-007 Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001 (TCT-ASTCT-CIBMTR 2025) - P1/2, P2 | "Adolescent patients 12-18 years old were enrolled in Phase 2 and received 900M WU-CART-007 cells on Day 1 following lymphodepleting chemotherapy (fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days). WU-CART-007 has shown efficacy and an acceptable safety profile in adolescent patients with R/R T-ALL/LBL. These promising results support the follow up Phase 2 trial to include children aged 1 year and above, with a potential exploratory cohort for patients with MRD positive disease after induction and consolidation chemotherapy."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Colorectal Cancer • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Lymphoma • Oncology • Rare Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results (ASH 2024) - P1/2, P2 | "In the Phase 2 portion, pts received a single infusion of 900 million WT-7 cells on Day 1 following enhanced lymphodepleting (eLD) chemotherapy (fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...Cytokine Release Syndrome (CRS) occurred in 13/13 (100%) pts; most (69%; 9/13) had G1-2 CRS events; four (31%) pts had G≥3 CRS, which was managed with steroids (75%), tocilizumab (100%), anakinra (25%)...WT-7 has demonstrated evidence of anti-leukemic activity with an acceptable safety profile in heavily pre-treated R/R T-ALL/LBL pts. A follow up study, NCT06514794, in R/R T-ALL/LBL including pediatric pts 1 year of age and older will begin enrolling in late 2024; exploratory MRDpos cohort may be initiated after safety is confirmed in the R/R setting."

CAR T-Cell Therapy • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Oncology • Otorhinolaryngology • Pediatrics • Pneumonia • Respiratory Diseases • Septic Shock • T Acute Lymphoblastic Leukemia • CD7

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Leukemia • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD7

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001 (ASH 2024) - P1/2, P2 | "In the Phase 2 portion, pts received 900M WT-7 cells on Day 1 following lymphodepleting chemotherapy (fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days). Given these promising results, the follow up Phase 2 trial will expand enrollment to include children 1 year of age and above, with the potential to open an exploratory cohort with patients with MRD positive disease following induction and consolidation chemotherapy will be initiated after additional safety data is collected in the R/R population. This study, NCT06514794, will begin enrolling in late 2024."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Colorectal Cancer • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Lymphoma • Oncology • Rare Diseases • T Acute Lymphoblastic Leukemia • CD7

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma (ASH 2024) - P1, P1/2 | "Patients receive "enhanced" lymphodepletion with fludarabine (30 mg/m2 daily x4) and cyclophosphamide (1000 mg/m2 daily x3) followed by WU-CART-007 infusion 3 days after the last dose of chemotherapy. CONCLUSION : WU-CART-007, a promising therapy in patients with relapsed/refractory T-NHL, has demonstrated early signs of activity in this heavily pretreated patient population. Study enrollment (NCT05377827) is ongoing to determine the safety and preliminary efficacy of WU-CART-007 in patients with CD7+ T-NHL and AML."

CAR T-Cell Therapy • Clinical • IO biomarker • P1 data • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Rare Diseases • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD7

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 (GlobeNewswire) - P1/2 | N=29 | NCT04984356 | Sponsor: Wugen, Inc. | "Results from Phase 1/2 showed continued anti-leukemic activity and clinically manageable safety in adults and adolescents. WU-CART-007 is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy under evaluation for treatment of patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL). Based on findings to date with WU-CART-007, including this week’s data, Wugen will initiate the first pivotal Phase 2 study for an off-the-shelf CD7-targeted CAR-T cell therapy."

P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting… (GlobeNewswire) - "Researchers will present Phase 1/2 updates and studies for its investigational cell therapies this week...'At this year’s ASH meeting, we will present clinical data from adult and adolescent patients that support our soon to open pivotal trial for patients with relapsed or refractory T-ALL/LBL'...The pivotal Phase 2 study is a single-arm trial evaluating the efficacy and safety of WU-CART-007 in patients with R/R T-ALL/LBL and T-ALL/LBL...Wugen researchers will also present the following abstracts for the company’s investigational memory natural killer cell therapy, WU-NK-101"

Clinical data • Acute Myelogenous Leukemia • T Acute Lymphoblastic Leukemia

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma (GlobeNewswire) - "Wugen, Inc...announced it will initiate a pivotal Phase 2 study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR-T cell therapy, WU-CART-007, in patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL)....The trial will enroll pediatric and adult patients at oncology centers in the United States, Europe, Asia and Australia."

New P2 trial • B Acute Lymphoblastic Leukemia • T Acute Lymphoblastic Leukemia

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Washington University School of Medicine | Recruiting ➔ Active, not recruiting | N=54 ➔ 6

CAR T-Cell Therapy • Enrollment change • Enrollment closed • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prolymphocytic Leukemia • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD7

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. (PubMed, Res Sq) - P1/2 | "WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356."

Journal • P1/2 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • Rare Diseases • T Acute Lymphoblastic Leukemia • CD7

WU-CART-007 1001: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov) - P1/2 | N=29 | Completed | Sponsor: Wugen, Inc. | Active, not recruiting ➔ Completed | N=44 ➔ 29 | Trial completion date: Aug 2026 ➔ Jun 2024 | Trial primary completion date: May 2026 ➔ Jun 2024

CAR T-Cell Therapy • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

A Phase 2 Study WU-CART-007 in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=125 | Not yet recruiting | Sponsor: Wugen, Inc.

CAR T-Cell Therapy • Minimal residual disease • New P2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

WU-CART-007, AN ALLOGENEIC CAR-T CELL TARGETING CD7, IS HIGHLY EFFECTIVE AGAINST RELAPSED/REFRACTORY (R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/LBL) (EHA 2024) - P1/2 | " In the Phase 2 portion, pts received 900M WU-CART-007 cells on Day 1 following lymphodepletingchemotherapy (30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...Cytokine Release Syndrome (CRS) occurred in 13/13 (100%) pts; most (69%; 9/13) had G1-2 CRS events; four (31%) pts had G≥3 events, which was managed with steroids (75%),tocilizumab (100%), anakinra (25%)... WU-CART-007 has demonstrated an acceptable safety profile and evidence of anti-leukemic activity in heavily pre-treated R/R T-ALL/LBL pts. A follow up study in R/R T-ALL/LBL includingpediatric pts < 12 years and an MRD cohort is projected to start in Q4 2024."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • Otorhinolaryngology • Pediatrics • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock • T Acute Lymphoblastic Leukemia • Transplantation • CD7

PRELIMINARY EFFECT OF ENHANCED LYMPHODEPLETION (ELD) ON WU-CART-007 IN TALL/LBL (EHA 2024) - P1/2 | "Two lymphodepleting (LD) chemotherapy regimens have been tested in our trial: standard LD (sLD; fludarabine 30 mg/m2/day x 3 days and cyclophosphamide 500 mg/m2/day x 3 days), and enhanced LD (eLD; fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...To evaluate potential contributing risk factors for infection inpts who received eLD, we analyzed total doses of steroids, anakinra, and tocilizumab received in associationwith CRS on infection severity...Increasing intensity of LD therapy, while successful in increasing expansion, persistence, and responses of WU-CART-007 in R/R T-ALL/LBL pts, was associated with higher incidence and severity of CRS and infections. Ourdata suggests that a contributing factor is the usage of immunosuppressing therapy for CRS. Hence, early useof steroid-sparing agents for the management of CRS may mitigate infection severity."

Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • CD7

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress (GlobeNewswire) - P1/2 | N=44 | NCT04984356 | Sponsor: Wugen, Inc. | "Key Phase 2 Findings: The presentation at EHA featured results with the recommended dose (RP2D) of WU-CART-007 administered in 13 patients at a median age 30 years who were heavily pre-treated and had a high burden of disease at the start of the study....Outcomes following WU-CART-007 treatment in the study surpassed current standard of care for R/R T-ALL/LBL and included: Composite complete remission rate (CRc) of 73% (8/11) (primary endpoint); Overall response rate of 91% (10/11; 2 partial response (PR) in patients with extramedullary disease, R/R T-LBL); Duration of response (DOR) (secondary endpoint): Median duration (mDOR) was 6.2 months (95% CI: 1.8, NE); Median follow up was 8.5 months (95% CI: 2.7, NE); 46% (5/11) patients remained in continuous remission at 4.3 to 8.6 months."

P2 data • Acute Lymphocytic Leukemia • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June (GlobeNewswire) - "Wugen, Inc...announced receipt of two new regulatory designations for its investigational CAR-T cell therapy, WU-CART-007, that it anticipates will expedite regulatory reviews on two continents. Specifically, Wugen received Regenerative Medicine Advanced Therapy (RMAT) designation in the United States and PRIME ('Priority Medicines') designation in the European Union for WU-CART-007 for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)....Regulators granted Wugen these designations following their reviews of data including results from the global Phase 1/2 clinical trial for the treatment of R/R T-ALL/LBL....The newest data from the Phase 1/2 study will be presented by Ibrahim Aldoss, M.D., City of Hope, on June 14 during the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain."

FDA event • P1/2 data • PRIME • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Novel approaches for diagnosis & treatment of acute lymphoblastic and myeloid leukemia (ICKSH 2024) - "For BCP-ALL, this mainly concerns the introduction of blinatumomab and inotuzumab ozogamicin, as well as the recently developed menin inhibitor revumenib, which is mainly be of relevance for KMT2A-rearranged (infant) ALL. Other menin inhibitors are also under development, such as ziftomenib and JNJ-75276617. Other targeted therapy options are mainly relevant in Philadelphia-chromosome positive leukemias, and in adult ALL the concept of che- mo-free induction therapy is already under development consisting of combinations of tyrosine kinase inhibitors (TKIs) such as imatinib, da- satinib or ponatinib, in combination with with steroids or blinatumomab, and challenging the need for SCT in this disease...Also for T-cell ALL, newer therapy options are available including CAR T-cell therapy, for example the allogenic off-the-shelf, fractricide-resistant CD7-targeted CAR-T cell therapy studies in the WU-CART-007 study. For AML, immunotherapy is less well advanced, but next to..."

Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Pediatrics • Solid Tumor • CBFA2T3 • CD123 • CD7 • FLT3 • GLIS2 • IL3RA • KMT2A • NUP98

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) (TCT-ASTCT-CIBMTR 2024) - P1/2 | "Most (72%; 13) pts had G1-2 CRS events; a single G3 CRS event was reported which resolved within 72 hours after receiving tocilizumab, steroids, and low-dose vasopressors. WU-CART-007 has demonstrated an acceptable safety profile and preliminary evidence of anti-leukemic activity. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL."

CAR T-Cell Therapy • IO biomarker • P1/2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • CCR7 • CD7